Competing interests
F.L. serves on the scientific advisory boards of Amgen, Novartis, Sanofi, and Vertex and on the speaker’s bureau for Miltenyi Biomedicine, Amgen, Novartis, Bristol Myers Squibb, Gilead, MEDAC, and SOBI.; P.M. reports consulting for Sobi, Miltenyi, and Amgen; the other authors declare no competing interests.
Ethics approval and consent to participate
All methods were performed in accordance with the relevant guidelines and regulations. Blinatumomab was administered on an off-label basis under the responsibility of the treating physicians, in accordance with Italian regulations governing the off-label use of approved medicinal products. Written informed consent was obtained from the patient’s legal guardians.
Consent for publication
Written informed consent for publication of the images was obtained from the patient’s legal guardians.
